Skip to main content

MADRIGAL PHARMACEUTICALS, INC.

For the period ended Dec 31, 2025. Filed Feb 19, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 19, 2026

MDGL$432.79+8.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

MADRIGAL PHARMACEUTICALS INC.
Date: February 19, 2026By:/s/ WILLIAM J. SIBOLD
William J. Sibold
President and Chief Executive Officer
(Principal Executive Officer)

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each individual whose signature appears below hereby constitutes and appoints William J. Sibold and Mardi Dier and each or either of them, acting individually, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Report, and to file the same, with all exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or any of them, or their or his or her substitutes, may lawfully do or cause to be done or by virtue hereof.

Pursuant to the requirements of the Exchange Act, as amended, this Annual Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

SignaturesTitleDate
/s/ WILLIAM J. SIBOLDPresident and Chief Executive Officer, Director(Principal Executive Officer)February 19, 2026
William J. Sibold
/s/ MARDI C. DIERExecutive Vice President and Chief Financial Officer (Principal Financial Officer)February 19, 2026
Mardi C. Dier
/s/ RITA THAKKARSenior Vice President and Chief Accounting Officer (Principal Accounting Officer)February 19, 2026
Rita Thakkar
/s/ JULIAN C. BAKERChair of the BoardFebruary 19, 2026
Julian C. Baker
/s/ REBECCA TAUB, M.D.DirectorFebruary 19, 2026
Rebecca Taub, M.D.
/s/ PAUL A. FRIEDMAN, M.D.DirectorFebruary 19, 2026
Paul A. Friedman, M.D.
/s/ RAYMOND CHEONG, M.D., PH.D.DirectorFebruary 19, 2026
Raymond Cheong, M.D., Ph.D.
/s/ RICHARD S. LEVY, M.D.DirectorFebruary 19, 2026
Richard S. Levy, M.D.
SignaturesTitleDate
/s/ JAMES M. DALYDirectorFebruary 19, 2026
James M. Daly
/s/ JACQUALYN FOUSE, Ph.D.DirectorFebruary 19, 2026
Jacqualyn Fouse, Ph.D.
/s/ DANIEL BRENNANDirectorFebruary 19, 2026
Daniel Brennan

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

Page
Report of Independent Registered Public Accounting Firm (PCAOB ID 238)F-2
Consolidated Financial Statements:
Consolidated Balance SheetsF-4
Consolidated Statements of OperationsF-5
Consolidated Statements of Comprehensive LossF-6
Consolidated Statements of Stockholders’ EquityF-7
Consolidated Statements of Cash FlowsF-8
Notes to Consolidated Financial StatementsF-9
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.